Different estrogen receptor structural domains are required for estrogen- and tamoxifen-dependent anti-proliferative activity in human mammary epithelial cells expressing an exogenous estrogen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 62, Issue 5-6, 1997, Pages 373-383

  Zajchowski, Deborah A ^a   Webster, Lynn ^a   Humm, Rhonda ^a   White III, Frank A ^a   Simmons, Sandra J ^a,b   Bartholdi, Marty ^a  

^a BAYER AG   (Germany)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GROWTH INHIBITOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MODULATION;

BASE SEQUENCE; BINDING SITES; BREAST; CELL DIVISION; CELL LINE; DNA; DNA PRIMERS; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYUNSATURATED ALKAMIDES; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSFECTION;

EID: 0031451978     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00052-6     Document Type: Article

References (49)

1. McGuire, W., Carbone, P. and Vollmer, R., Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975.
2. Zajchowski D. A. and Sager R., Induction of estrogen-regulated genes differs in immortal and tumorigenic human mammary epithelial cells expressing a recombinant estrogen receptor. Molecular Endocrinology 5 (1991) 1613-1623.
3. Zajchowski D. A., Sager R. and Webster L., Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Research 53 (1993) 5004-5011.
4. Jiang S. Y. and Jordan V. C., Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. Journal of the National Cancer Institute 84 (1992) 580-591.
5. Garcia M., Derocq D., Freiss G. and Rochefort H., Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proceedings of the National Academy of Sciences USA 89 (1992) 11538-11542.
6. Green S. and Chambon P., Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 4 (1988) 309-314.
7. Gaub M. P., Bellard M., Scheuer I., Chambon P. and Sassone Corsi P., Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63 (1990) 1267-1276.
8. Philips A., Chalbos D. and Rochefort H., Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. Journal of Biological Chemistry 268 (1993) 14103-14108.
9. Krishnan V., Wang X. and Safe S., Estrogen receptor - Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. Journal of Biological Chemistry 269 (1994) 15912-15917.
10. Meyer M. E., Gronemeyer H., Turcotte B., Bocquel M. T., Tasset D. and Chambon P., Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57 (1989) 433-442.
11. Zajchowski, D. A., Webster, L., Dissection of the mechanism of estrogen and tamoxifen-dependent anti-proliferative effects on ER-transfected human mammary epithelial cells. Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 1994 (Abstract 1583).
12. Parker M. G., Arbuckle N., Dauvois S., Danielian P. and White R., Structure and function of the estrogen receptor. Annals of the New York Academy of Science 684 (1993) 119-126.
13. Gronemeyer H., Transcription activation by estrogen and progesterone receptors. Annual Review of Genetics 25 (1991) 89-123.
14. Green S., Walter P., Kumar V., Krust A., Bornert J. M., Argos P. and Chambon P., Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139.
15. Green S. and Chambon P., Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature 325 (1987) 75-78.
16. Green S., Kumar V., Theulaz I., Wahli W. and Chambon P., The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO Journal 7 (1988) 3037-3044.
17. Kumar V., Green S., Stack G., Berry M., Jin J. R. and Chambon P., Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951.
18. Stampfer M. R. and Bartley J. C., Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proceedings of the National Academy of Sciences USA 82 (1985) 2394-2398.
19. Band V. and Sager R., Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proceedings of the National Academy of Sciences USA 86 (1989) 1249-1253.
20. Greene G. L., Sobel N. B., King W. J. and Jensen E. V., Immunochemical studies of estrogen receptors. Journal of Steroid Biochemistry 20 (1984) 51-56.
21. Chirgwin J. M., Przybyla A. E., MacDonald R. J. and Rutter W. J., Isolation of biologically active ribonucleic acid from sources enriched in ribonucleases. Biochemistry 18 (1979) 5294-5299.
22. Berry M., Metzger D. and Chambon P., Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal 9 (1990) 2811-2818.
23. Furr B. J. and Jordan V. C., The pharmacology and clinical uses of tamoxifen. Pharmacology and Therapeutics 25 (1984) 127-205.
24. Tora L., Mullick A., Metzger D., Ponglikitmongkol M., Park I. Chambon P., The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO Journal 8 (1989) 1981-1986.
25. Jiang S. Y., Langan Fahey S..M., Stella A. L., McCague R. Jordan V. C., Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Molecular Endocrinology 6 (1992) 2167-2174.
26. Kushner P. J., Hort E., Shine J., Baxter J. D. and Greene G. L., Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Molecular Endocrinology 4 (1990) 1465-1473.
27. Nielsen D. A. and Shapiro D. J., Insights into hormonal control of messenger RNA stability. Molecular Endocrinology 7 (1990) 953-957.
28. Kumar V. and Chambon P., The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156.
29. Dubik D. and Shiu R. P., Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 (1992) 1587-1594.
30. Sukovich D. A., Mukherjee R. and Benfield P. A., A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element. Molecular Cell Biology 14 (1994) 7134-7143.
31. Ray A., Prefontaine K. E. and Ray P., Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. Journal of Biological Chemistry 269 (1994) 12940-12946.
32. Stein B. and Yang M. X., Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/ EBP beta. Molecular Cell Biology 15 (1995) 4971-4979.
33. Umayahara Y., Kawamori R., Watada H., Imano E., Iwama N., Morishima T., Yamasaki Y., Kajimoto Y. and Kamada T., Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. Journal of Biological Chemistry 269 (1994) 16433-16442.
34. Elgort M. G., Zou A., Marschke K. B. and Allegretto E. A., Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α1 promoter via a novel sequence. Molecular Endocrinology 10 (1996) 477-487.
35. Webb P., Lopez G. N., Uht R. M. and Kushner P. J., Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 (1995) 443-456.
36. Danielian P. S., White R., Lees J. A. and Parker M..G., Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO Journal 11 (1992) 1025-1033.
37. Cavailles V., Dauvois S., L'Horset F., Lopez G., Hoare S., Kushner P. J. and Parker M. G., Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO Journal 14 (1995) 3741-3751.
38. LeDouarin B., Zechel C., Gamier J. M., Lutz Y., Tora L., Pierrat P., Heery D., Gronemeyer H., Chambon P. and Losson R., The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO Journal 14 (1995) 2020-2033.
39. Halachmi S., Marden E., Martin G., MacKay H., Abbondanza C. and Brown M., Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264 (1994) 1455-1458.
40. Onate S. A., Tsai S. Y., Tsai M. J. and O'Malley B. W., Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 (1995) 1354-1357.
41. Tzukerman M. T., Esty A., Santiso Mere D., Danielian P., Parker M. G., Stein R. B., Pike J. W. and McDonnell D. P., Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8 (1994) 21-30.
42. Metzger D., Ali S., Bornert J. M. and Chambon P., Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. Journal of Biological Chemistry 270 (1995) 9535-9542.
43. Bocquel M. T., Kumar V., Stricker C., Chambon P. and Gronemeyer H., The contribution of the N-and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Research 17 (1989) 2581-2595.
44. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E. Chambon P., The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487.
45. Tasset D., Tora L., Fromental C., Scheer E. and Chambon P., Distinct classes of transcriptional activating domains function by different mechanisms. Cell 62 (1990) 1177-1187.
46. Webb P., Lopez G. N., Greene G. L., Baxter J. D. and Kushner P. J., The limits of the cellular capacity to mediate an estrogen response. Molecular Endocrinology 6 (1992) 157-167.
47. Sadovsky Y., Webb P., Lopez G., Baxter J..D., Fitzpatrick P. M., Gizang Ginsberg E., Cavailles V., Parker M. G. and Kushner P. J., Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Molecular Cell Biology 15 (1995) 1554-1563.
48. Chen T. K., Smith L. M., Gebhardt D. K., Birrer M. J. and Brown P. H., Activation and inhibition of the AP-1 complex in human breast cancer cells. Molecular Carcinogenesis 15 (1996) 215-226.
49. Doucas V., Spyrou G. and Yaniv M., Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells. EMBO Journal 10 (1991) 2237-2245.